6 completed, 3 recruiting, 1 active not recruiting, 1 terminated. 8 Phase 1, 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 6, Active not recruiting 1, Recruiting 1 |
| Phase 3 | 2 | Recruiting 1, Terminated 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Corvus Pharmaceuticals, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa Soquelitinib - Hidradenitis Suppurativa (HS) | Phase 1 | Recruiting | Corvus Pharmaceuticals, Inc. | 25 | 2026-09-17 | 2026-10-15 |
| Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD Soquelitinib, Placebo - Atopic Dermatitis, Atopic Dermatitis Eczema | Phase 2 | Recruiting | Corvus Pharmaceuticals, Inc. | 200 | 2026-02-01 | 2026-03-05 |
| Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma Soquelitinib, Belinostat, Pralatrexate - Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma | Phase 3 | Recruiting | Corvus Pharmaceuticals, Inc. | 150 | 2024-10-02 | 2026-09-25 |
| Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD Soquelitinib, Placebo - Atopic Dermatitis | Phase 1 | Completed | Corvus Pharmaceuticals, Inc. | 82 | 2024-04-16 | 2026-03-12 |
| CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients CPI-006 2 mg/kg + SOC, CPI-006 1 mg/kg + SOC, Placebo + SOC - Covid-19 | Phase 3 | Terminated | Corvus Pharmaceuticals, Inc. | 46 | 2021-02-25 | 2022-09-21 |
| Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients CPI-006, Standard of Care - COVID-19 | Phase 1 | Completed | Corvus Pharmaceuticals, Inc. | 30 | 2020-07-01 | 2021-07-21 |
| Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma Ciforadenant, daratumumab - Multiple Myeloma | Phase 1 | Completed | Corvus Pharmaceuticals, Inc. | 7 | 2020-02-20 | 2022-03-11 |
| A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma CPI-818 - T-cell Lymphoma | Phase 1 | Active not recruiting | Corvus Pharmaceuticals, Inc. | 151 | 2019-05-03 | 2026-10-22 |
| CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab - Non-Small Cell Lung Cancer, Renal Cell Cancer | Phase 1 | Completed | Corvus Pharmaceuticals, Inc. | 117 | 2018-04-25 | 2023-12-21 |
| Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 in Fed and Fasted Healthy Male and Female Subjects CPI-444 Capsules, CPI-444 Tablets - Healthy Subjects | Phase 1 | Completed | Corvus Pharmaceuticals, Inc. | 24 | 2017-07-20 | 2018-01-26 |
| Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers Ciforadenant, Ciforadenant + atezolizumab - Renal Cell Cancer, Metastatic Castration Resistant Prostate Cancer | Phase 1 | Completed | Corvus Pharmaceuticals, Inc. | 502 | 2016-01-01 | 2021-08-30 |
COVID-19 (2) · Carcinoma, Renal Cell (2) · Coronavirus Infections (2) · Dermatitis, Atopic (2) · Kidney Neoplasms (2) · Lymphoma, T-Cell (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Eczema (1) · Endometrial Neoplasms (1) · Hidradenitis Suppurativa (1) · Immunoblastic Lymphadenopathy (1) · Lung Neoplasms (1) · Lymphoma, Large-Cell, Anaplastic (1)
ciforadenant (4) · CPI-006 (3) · 10-propargyl-10-deazaaminopterin (1) · Standard of Care (1) · atezolizumab (1) · belinostat (1) · daratumumab (1) · pembrolizumab (1)
United States (11) · Australia (4) · Canada (3) · Argentina (1) · Brazil (1) · Chile (1) · China (1) · Colombia (1) · Germany (1) · Italy (1) · Mexico (1) · Peru (1) · South Korea (1) · Spain (1) · Ukraine (1)
Isin Sinem Bagci, MD (2) · Suresh Mahabhashyam, MD, MPH (2) · Deborah Strahs (1) · Mehrdad Mobasher, MD, MPH (1) · S Mahabhashyam, MD (1) · S. Mahabhashyam, MD, MPH (1) · S. Mahabhashyam, MD. MPH (1) · Suresh Mahabhashyam, MD (1)